Details of the Drug

General Information of Drug (ID: DM3V7QO)

Drug Name
Vatelizumab
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
DrugBank ID
DB12346
TTD ID
D0X9UA

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-2/beta-1 (ITGA2/B1) TTMSB0A ITA2_HUMAN-ITB1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02222948) Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis. U.S. National Institutes of Health.
2 Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146.